Temocaprilat is the active metabolite of temocapril, an angiotensin-converting enzyme (ACE) inhibitor used primarily in the treatment of hypertension. It works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby promoting vasodilation and reducing blood pressure. Due to its tissue-targeting properties, especially in the heart and blood vessels, temocaprilat contributes to improved cardiovascular outcomes by reducing afterload and myocardial oxygen demand. It is particularly beneficial in patients with heart failure or left ventricular dysfunction following myocardial infarction. Additionally, temocaprilat may offer renal protective effects in diabetic patients by reducing proteinuria and slowing the progression of kidney damage associated with chronic hypertension and diabetes. Its pharmacokinetic profile allows for once-daily dosing, enhancing patient compliance in long-term management of cardiovascular diseases.